{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:54:24Z","timestamp":1777593264600,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:00:00Z","timestamp":1498089600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s11060-017-2529-2","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T09:11:38Z","timestamp":1498122698000},"page":"331-338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation"],"prefix":"10.1007","volume":"134","author":[{"given":"Jason K.","family":"Molitoris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan James","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajal A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liam T.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahed N.","family":"Badiyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haley","family":"Gittleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill S.","family":"Barnholtz-Sloan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soren M.","family":"Bentzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim J.","family":"Kruser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minesh P.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,22]]},"reference":[{"key":"2529_CR1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11910-013-0347-2","volume":"13","author":"OL Chinot","year":"2013","unstructured":"Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloeguen Y, Cloughesy TF (2013) Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep 13:347. doi:\n                        10.1007\/s11910-013-0347-2","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"Suppl 4","key":"2529_CR2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","volume":"17","author":"QT Ostrom","year":"2015","unstructured":"Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008\u20132012. Neuro Oncol 17(Suppl 4):iv1\u2013iv62. doi:\n                        10.1093\/neuonc\/nov189","journal-title":"Neuro Oncol"},{"key":"2529_CR3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"2529_CR4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens A, Gorlia T, Hamou M, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997\u20131003","journal-title":"N Engl J Med"},{"key":"2529_CR5","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1093\/neuonc\/nos087","volume":"14","author":"JS Barnholtz-Sloan","year":"2012","unstructured":"Barnholtz-Sloan JS, Yu C, Sloan AE, Vengoechea J, Wang M, Dignam JJ, Vogelbaum MA, Sperduto PW, Mehta MP, Machtay M et al (2012) A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol 14:910\u2013918. doi:\n                        10.1093\/neuonc\/nos087","journal-title":"Neuro Oncol"},{"key":"2529_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(07)70384-4","volume":"9","author":"T Gorlia","year":"2008","unstructured":"Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A et al (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981\/CE.3. Lancet Oncol 9:29\u201338. doi:\n                        10.1016\/S1470-2045(07)70384-4","journal-title":"Lancet Oncol"},{"key":"2529_CR7","doi-asserted-by":"crossref","first-page":"e104455","DOI":"10.1371\/journal.pone.0104455","volume":"9","author":"A Etcheverry","year":"2014","unstructured":"Etcheverry A, Aubry M, Idbaih A, Vauleon E, Marie Y, Menei P, Boniface R, Figarella-Branger D, Karayan-Tapon L, Quillien V (2014) DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide. PLoS ONE 9:e104455","journal-title":"PLoS ONE"},{"key":"2529_CR8","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","volume":"31","author":"MR Gilbert","year":"2013","unstructured":"Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31:4085\u20134091. doi:\n                        10.1200\/JCO.2013.49.6968","journal-title":"J Clin Oncol"},{"key":"2529_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699\u2013708. doi:\n                        10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"},{"key":"2529_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now208","author":"H Gittleman","year":"2016","unstructured":"Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB, Lo SS, Machtay M, Sloan AE, Sulman EP et al (2016) An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology RTOG 0525 and 0825. Neuro Oncol. doi:\n                        10.1093\/neuonc\/now208","journal-title":"Neuro Oncol"},{"key":"2529_CR11","doi-asserted-by":"publisher","first-page":"495-015-1023-4","DOI":"10.1186\/s13063-015-1023-4","volume":"16","author":"T Kennedy-Martin","year":"2015","unstructured":"Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J (2015) A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials 16:495-015-1023-4. doi:\n                        10.1186\/s13063-015-1023-4","journal-title":"Trials"},{"key":"2529_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:43.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361\u2013387. doi:\n                        10.1002\/(SICI)1097-0258(19960229)15:43.0.CO;2-4","journal-title":"Stat Med"},{"key":"2529_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1215\/15228517-2007-038","volume":"10","author":"G Filippini","year":"2008","unstructured":"Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D, Farina R, Farinotti M, Fariselli L, Finocchiaro G et al (2008) Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol 10:79\u201387. doi:\n                        10.1215\/15228517-2007-038","journal-title":"Neuro Oncol"},{"key":"2529_CR14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","volume":"95","author":"M Lacroix","year":"2001","unstructured":"Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190\u2013198","journal-title":"J Neurosurg"},{"key":"2529_CR15","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00701-011-1001-x","volume":"153","author":"W Stummer","year":"2011","unstructured":"Stummer W, van den Bent, Martin J, Westphal M (2011) Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir 153:1211\u20131218","journal-title":"Acta Neurochir"},{"key":"2529_CR16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11060-010-0500-6","volume":"104","author":"ML Siker","year":"2011","unstructured":"Siker ML, Wang M, Porter K, Nelson DF, Curran WJ, Michalski JM, Souhami L, Chakravarti A, Yung WA, DelRowe J (2011) Age as an independent prognostic factor in patients with glioblastoma: a Radiation Therapy Oncology Group and American College of Surgeons National Cancer Data Base comparison. J Neurooncol 104:351\u2013356","journal-title":"J Neurooncol"},{"key":"2529_CR17","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1158\/1055-9965.EPI-14-0275","volume":"23","author":"JP Thakkar","year":"2014","unstructured":"Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, Villano JL (2014) Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomark Prev 23:1985\u20131996. doi:\n                        10.1158\/1055-9965.EPI-14-0275","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2529_CR18","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2009.21.9832","volume":"27","author":"M Sanson","year":"2009","unstructured":"Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150\u20134154","journal-title":"J Clin Oncol"},{"key":"2529_CR19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765\u2013773","journal-title":"N Engl J Med"},{"key":"2529_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1215\/15228517-2009-025","volume":"11","author":"K Ichimura","year":"2009","unstructured":"Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, Collins VP (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341\u2013347. doi:\n                        10.1215\/15228517-2009-025","journal-title":"Neuro Oncol"},{"key":"2529_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462\u2013477. doi:\n                        10.1016\/j.cell.2013.09.034","journal-title":"Cell"},{"key":"2529_CR22","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","volume":"372","author":"JE Eckel-Passow","year":"2015","unstructured":"Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV (2015) Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499\u20132508","journal-title":"N Engl J Med"},{"key":"2529_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.6020","author":"EH Bell","year":"2017","unstructured":"Bell EH, Pugh SL, McElroy JP, Gilbert MR, Mehta M, Klimowicz AC, Magliocco A, Bredel M, Robe P, Grosu A (2017) Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era: a correlative analysis based on NRG oncology RTOG 0525. JAMA Oncol. doi:\n                        10.1001\/jamaoncol.2016.6020","journal-title":"JAMA Oncol"},{"key":"2529_CR24","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1158\/1078-0432.CCR-09-3106","volume":"16","author":"SA Grossman","year":"2010","unstructured":"Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, Fisher J, NABTT CNS Consortium (2010) Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 16:2443\u20132449. doi:\n                        10.1158\/1078-0432.CCR-09-3106","journal-title":"Clin Cancer Res"},{"key":"2529_CR25","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","volume":"13","author":"W Wick","year":"2012","unstructured":"Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707\u2013715","journal-title":"Lancet Oncol"},{"key":"2529_CR26","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","volume":"13","author":"A Malmstr\u00f6m","year":"2012","unstructured":"Malmstr\u00f6m A, Gr\u00f8nberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916\u2013926","journal-title":"Lancet Oncol"},{"key":"2529_CR27","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1200\/JCO.2015.62.6606","volume":"33","author":"W Roa","year":"2015","unstructured":"Roa W, Kepka L, Kumar N, Sinaika V, Matiello J, Lomidze D, Hentati D, Guedes de Castro D, Dyttus-Cebulok K, Drodge S (2015) International Atomic Energy Agency randomized phase III study of radiation therapy in elderly and\/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 33:4145\u20134150","journal-title":"J Clin Oncol"},{"key":"2529_CR28","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","volume":"376","author":"JR Perry","year":"2017","unstructured":"Perry JR, Laperriere N, O\u2019Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027\u20131037","journal-title":"N Engl J Med"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-017-2529-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-017-2529-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-017-2529-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T09:24:57Z","timestamp":1503566697000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-017-2529-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,22]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["2529"],"URL":"https:\/\/doi.org\/10.1007\/s11060-017-2529-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,22]]}}}